You can buy or sell DFFN and other stocks, options, ETFs, and crypto commission-free!
Diffusion Pharmaceuticals Inc. Common Stock, also called Diffusion Pharmaceuticals, is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. Read More The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
52 Week High
52 Week Low
Yahoo FinanceMay 9
Diffusion Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
Enrollment in Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke to begin in Q3 CHARLOTTESVILLE, Va., May 09, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for the three months ended March 31, 2019 and provided a business update. During the first...
Markets InsiderMay 2
6 Top Gainers In Pharma Sector (DFFN, QTNT, ORGO...)
(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Diffusion Pharmaceuticals Inc. (DFFN) Diffusion Pharma is a clinical stage biotechnology company developing treatments for life-threatening medical conditions. Gained 91.56% to close Thursday's (May 2) trading at $5.90. News: No news Clinical Trials: The Company's lead drug candidate is Trans Sodium Crocinate. A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer,...
-$0.90 per share
-$0.81 per share